PhaseRx, Inc. PZRX
Set alert
No live quote for PZRX yet.
- Open
- 0.30
- Prev close
- 0.2806
- Mkt cap
- 3.28M
- Vol
- 1.05M
- Avg vol
- 1.08M
- EPS
- -1.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.275
- High
- 0.34
- Forward P/E
- -0.21
- Beta
- 0.00
- Short ratio
- 0.05
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.364825
- 200-d avg
- 0.657877
- 1y target
- 12.00
Key statistics
- Market cap
- 3.28M
- Enterprise value
- 3.46M
- Trailing P/E
- 0.00
- Forward P/E
- -0.21
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.19
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.68M
- Total cash
- 5.26M
- Total debt
- 5.44M
- Return on equity
- -228.17%
- Shares outstanding
- 11.69M
- Short % of float
- 0.13%
- 50-day average
- 0.364825
- 200-day average
- 0.657877
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 16, 2016 | Roth Capital | init | — | Buy |
About PhaseRx, Inc.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington. On December 11, 2017, PhaseRx, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- phaserx.com
News
Your note
Sign in to keep a note on PZRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES INC | Beneficial Owner (10% or more) | Ownership Statement | May 16, 2016 | 0 |
| ATWOOD BRIAN G | Director | Sale | May 22, 2016 | 0 |
| GILLIS STEVEN | Director | Sale | May 22, 2016 | 10,048 |
| JOHNSON PAUL H | Director | Ownership Statement | May 16, 2016 | 73,794 |
| OVERELL ROBERT W | Officer | Ownership Statement | May 16, 2016 | 0 |
| ULEVITCH RICHARD J | Director | Purchase | May 22, 2016 | 0 |